Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06693531 · ClinicalTrials.gov registry record
A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
A clinical trial of Eosinophilic Esophagitis (EoE), sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- 350
- Enrollment target
- 20
- Study locations
NCT06693531 is a study of Eosinophilic Esophagitis (EoE) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 350 participants, above the 91-participant average among 10 other Eosinophilic Esophagitis (EoE) trials with a reported enrollment target (285% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT06693531, a study of Eosinophilic Esophagitis (EoE), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab). The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE. Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward. Patient questionnaires will measure the following: * How EoE makes one feel * EoE signs and/or symptoms, eg, how difficult it is to swallow * How EoE affects quality-of-life * How EoE impacts aspects of daily life * How EoE symptoms have changed throughout the study
Conditions Studied
Interventions
- DRUG dupilumab
Study Locations (20)
California
- Scripps Clinic - La Jolla
- University of California Los Angeles (UCLA) - Los Angeles
- University of Southern California Keck School of Medicine - Los Angeles
- University of California, San Francisco - Oakland
- University of California San Francisco (UCSF) - San Francisco
Colorado
- Childrens Hospital Colorado - Aurora
- University of Colorado Anschutz Medical Campus - Aurora
- Rocky Mountain Gastroenterology - Littleton
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
- Northwestern University, Feinberg School of Medicine - Chicago
- Comprehensive Gastrointestinal Health, LLC - Libertyville
Arizona
- Phoenix Childrens Hospital - Phoenix
- Arizona Digestive Health/GI Alliance - Sun City
Connecticut
- UConn Health - The Carole and Ray Neag Comprehensive Cancer Center - Farmington
- Yale School of Medicine - New Haven
Florida
- Gastroenterology of Greater Orlando - Orange City
- Orlando Health - Orlando
Georgia
- Emory Healthcare, Emory Clinic - Atlanta
- GI Care for Kids LLC - Atlanta
Arkansas
- Arkansas Childrens Hospital - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2024-11-22 |
| Est. Completion | 2030-05-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06693531
The ClinicalTrials.gov registry entry for NCT06693531 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 91-participant average among 10 other Eosinophilic Esophagitis (EoE) trials with a reported enrollment target (285% higher). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Eosinophilic Esophagitis (EoE) appearing as the primary indexed condition, and to 1 intervention - of which dupilumab is the first listed.
NCT06693531 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Colorado, Illinois.
Frequently Asked Questions
What is clinical trial NCT06693531 about?
NCT06693531 is a clinical study titled "A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care". This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab). The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE. Possible benefits to others inc...
What is the current status of trial NCT06693531?
This trial is currently recruiting. The enrollment target is 350 participants. The study started on 2024-11-22. Estimated completion is 2030-05-22.
What conditions does trial NCT06693531 study?
This clinical trial studies the following conditions: Eosinophilic Esophagitis (EoE).
What interventions are being tested in trial NCT06693531?
The interventions under investigation include: dupilumab (DRUG).
Who is sponsoring clinical trial NCT06693531?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06693531 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Esophagitis (EoE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Surface EMG Testing on Swallowing in EoE Patients
RECRUITING
-
Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
RECRUITING · Phase 4
-
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
RECRUITING · Phase 3
-
Esophageal String Test Monitoring to Monitor Eosinophilic Esophagitis During Oral Immunotherapy
RECRUITING
-
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
ACTIVE NOT RECRUITING · Phase 2
-
Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.